SubHero Banner

Xtampza® ER (oxycodone) – Label updates

November 7, 2017 – Collegium Pharmaceuticals announced the FDA approval of updates to the Xtampza ER (oxycodone) drug label regarding data from pharmacokinetic and human abuse potential studies, along with support from in vitro data, indicating that Xtampza ER has physicochemical properties that are expected to reduce abuse via the oral and intranasal routes.

Download PDF